| Professional Services Industry | Industrials Sector | Mr. David Andrew Regan CEO | CNSX Exchange | - ISIN |
| Canada Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Sona Nanotech Inc. is a pioneering nanotechnology life sciences firm established in 2013 and headquartering in Halifax, Canada. The company is at the forefront of developing innovative therapeutic and diagnostic solutions primarily in the cancer treatment sector and in other critical healthcare diagnostics. Utilizing nanotechnology, Sona Nanotech Inc. focuses on creating highly specific treatments and rapid diagnostic tools, aiming to improve patient outcomes and provide faster, more accurate health insights.
A novel approach by Sona Nanotech which uses heat generated from nanoparticles to treat cancer by targeting only cancerous cells, leaving the healthy cells unharmed. This therapy is being developed to provide a less invasive option than traditional treatments, with the hope of reducing side effects and improving recovery times.
This innovative treatment method focuses on colorectal cancer by using nanotechnology to deliver medicines more effectively to the cancer cells. Sona Nanotech’s strategy enhances the drug's impact on the targeted cancer cells while minimizing the distribution of the drug to non-cancerous cells, potentially lessening the side effects commonly associated with cancer treatments.
Specializing in the production of gold nanoparticles, Sona Nanotech Inc. leverages these particles' unique properties for various applications, including medical imaging and as carriers for drug delivery. The gold nanoparticles can be used to improve the precision and effectiveness of diagnostic and therapeutic practices.
The company designs rapid diagnostic tests based on the lateral flow assay technology. These tests offer quick, reliable results for various applications, including but not limited to, infectious disease detection, environmental testing, and food safety. The portability and ease of use make these tests an essential tool for rapid decision-making in healthcare and beyond.
Addressing the critical need for early detection of tuberculosis in cattle, Sona Nanotech has developed a specific diagnostic test for Bovine TB. Early detection is crucial to prevent the spread of the disease, ensuring the health of cattle and reducing the potential risk to humans.
Expanding their reach beyond infectious diseases and cancer, Sona Nanotech is also developing rapid screening tests for concussions. These tests are designed to be administered immediately after an injury occurs, providing quick information about the potential severity of a concussion and aiding in the decision-making process for further medical care.